Hepatitis B and Liver Damage: Why Regular Liver Function Tests Matter If You Are a Carrier
Last updated: 29 Sep 2026
You were told years ago that you are a hepatitis B carrier. Maybe it was discovered during a blood donation, a pre-employment screening, or a routine health check. The doctor said something reassuring: "You are just a carrier. It's not active. You don't need treatment. Come back if anything changes."
That was the last time you thought about it.
This is an extraordinarily common scenario in Singapore, where approximately 4 to 6 per cent of the population are chronic hepatitis B carriers. Most were infected at birth or in early childhood, before the universal vaccination programme began. Most have no symptoms. Most feel completely well. And 64 per cent are not being monitored regularly.
That 64 per cent is the number that matters. Because hepatitis B does not announce its progression. It does not produce symptoms as it damages your liver. And the complications it causes, chronic hepatitis, cirrhosis, and liver cancer, develop silently over years and decades. The only way to detect them is through regular testing. And the majority of carriers are not getting tested.
Liver Function Test for peace of mind
Patient-first, Holistic, Dedicated Healthcare
What Being a "Carrier" Actually Means
Chronic hepatitis B means the virus is present in your body permanently. Your immune system was unable to clear it (typically because the infection was acquired in infancy, when the immune system is immature), and the virus has integrated into your liver cells.
Being a carrier does not mean nothing is happening. The virus is replicating at varying levels, and your immune system is continuously interacting with it. This interaction determines whether the virus remains relatively quiet (inactive carrier state) or becomes active (chronic hepatitis), causing ongoing liver inflammation and damage.
The SingHealth hepatitis B resource notes that 25 to 50 per cent of chronic carriers can expect to develop serious liver complications during their lifetime. The National University Hospital reports that over 500,000 people die annually worldwide from hepatitis B-related liver disease. And hepatitis B carriers are 100 to 200 times more likely to develop liver cancer compared to non-carriers.
These are not small risks. And they apply to carriers who feel perfectly well, who have no symptoms, and who were told they were "just carriers."
Why Hepatitis B Is Called the Silent Disease
Chronic hepatitis B earns this description because it can damage your liver for years without producing a single noticeable symptom. The liver has enormous functional reserve. Inflammation can be active, fibrosis can be developing, and even early cirrhosis can be present while you feel completely normal, go about your daily life, and have no reason to suspect anything is wrong.
Symptoms, when they eventually appear, tend to indicate advanced disease: persistent fatigue, unexplained weight loss, jaundice (yellowing of the skin and eyes), abdominal swelling (ascites), easy bruising, and dark urine. By the time these symptoms develop, the liver has typically sustained significant damage, and the treatment options are more limited.
This is precisely why regular monitoring matters. The purpose of surveillance is not to wait for symptoms. It is to detect changes, active inflammation, rising viral levels, early fibrosis, or suspicious liver lesions, at a stage when intervention can change the outcome.
What Can Happen If Monitoring Lapses
A screening study of 387 asymptomatic hepatitis B carriers in Singapore found that 5.4 per cent had undiagnosed complications at the time of screening: chronic hepatitis requiring treatment, compensated cirrhosis, and one case of early liver cancer that was successfully treated because it was caught through screening.
These were carriers who felt well. Who had no symptoms. Who would not have known about their complications without the screening programme. The man with early liver cancer would almost certainly have presented years later with advanced, less treatable disease if the screening had not detected it incidentally.
The progression from inactive carrier to active hepatitis to fibrosis to cirrhosis to liver cancer is not linear or predictable. A carrier can remain stable for decades and then experience viral reactivation triggered by immune suppression (from medication, chemotherapy, or other illness), stress, or age-related immune changes. Without monitoring, this reactivation goes undetected until the consequences are advanced.
What Regular Monitoring Involves
The monitoring recommended for hepatitis B carriers is straightforward, non-invasive, and well-established in clinical guidelines.
Liver function tests (ALT, AST, GGT). These detect active liver inflammation. As we explained in our blog on liver markers, elevated ALT in a hepatitis B carrier is a red flag that the virus has become active and is causing ongoing liver cell damage. Normal ALT is reassuring but does not guarantee the virus is completely inactive, which is why it must be checked regularly rather than once.
Alpha-fetoprotein (AFP). A blood marker used to screen for liver cancer. AFP is not perfectly sensitive (some liver cancers do not produce it), but it is a useful screening tool when combined with imaging. Elevated AFP in a hepatitis B carrier warrants urgent further investigation.
Liver ultrasound. A six-monthly ultrasound examines the liver for structural changes: early nodules, suspicious lesions, signs of cirrhosis, and increased liver size. Early liver cancer detected on ultrasound is often curable through surgical resection. Advanced liver cancer detected through symptoms is often not.
Hepatitis B viral load (HBV DNA). Measures the amount of virus replicating in your blood. A high viral load indicates active replication and increased risk of liver damage. This guides decisions about whether antiviral treatment is warranted.
HBeAg status. Hepatitis B e-antigen indicates a phase of higher viral replication. Changes in HBeAg status (seroconversion from positive to negative) are clinically significant and affect management decisions.
Full blood count. Low platelets can indicate advancing fibrosis or early cirrhosis. This is a simple but important marker that can be checked alongside liver function tests.
The recommended frequency for most carriers is every six months. This interval is based on the doubling time of liver cancer (the time it takes a tumour to double in size) and the probability of detecting cancers at a curable stage.
What About Your Family
Hepatitis B is transmitted through blood and bodily fluids, including from mother to child during birth. If you are a carrier, your family members should be tested.
Your partner should be tested for hepatitis B and, if not immune, vaccinated. The hepatitis B vaccine is highly effective and provides long-lasting protection.
Your children should have been vaccinated at birth (this has been part of Singapore's national immunisation programme since 1987). If you are unsure of their vaccination status, a hepatitis B test can confirm whether they are protected, infected, or need vaccination.
Your siblings and parents may also be carriers, particularly if your mother was the source of your infection. Encouraging family screening is one of the most impactful things you can do.
Alcohol and Hepatitis B: A Dangerous Combination
As we discussed in our blog on alcohol and liver damage, alcohol adds direct hepatotoxic stress to a liver that is already under viral assault. Hepatitis B carriers who drink regularly have significantly accelerated rates of fibrosis progression, cirrhosis development, and liver cancer compared to carriers who do not drink.
For hepatitis B carriers, there is no safe level of regular alcohol consumption. The combination of chronic viral infection and regular alcohol use compounds the risk multiplicatively, not additively. If you are a carrier, reducing or eliminating alcohol is one of the most protective steps you can take for your liver.
The Monitoring Gap Is the Danger
Hepatitis B is not dangerous because it is untreatable. It is dangerous because it is unmonitored. The virus, the treatments, and the screening tools have all been well-established for decades. What is missing is the regular follow-up that catches complications at a treatable stage.
If you are a hepatitis B carrier and you have not had your liver checked in the past 12 months, you are part of the 64 per cent who are not being monitored. The screening takes a single visit. A hepatitis B test alongside a liver function test tells you where your liver stands today. A broader health screening at our GP clinic adds the metabolic context (blood sugar, cholesterol, kidney function) that determines your overall risk profile.
Your status as a carrier has not changed. But your liver may have. The only way to know is to check.
Liver Function Test for peace of mind
Patient-first, Holistic, Dedicated Healthcare
Medical Disclaimer & Limitation of Liability
The content provided in this post is strictly for informational and educational purposes. Just as we fiercely defend our right to publish general health information, we establish an uncompromising boundary: this material is never a substitute for personalised, professional medical advice, diagnosis, or treatment.
Reading this content does not establish a doctor-patient relationship. You possess the sovereign right and responsibility to manage your own health, which means you must consult your own qualified physician before making any medical decisions based on what you read here. We explicitly disclaim all medicolegal liability for any injury, loss, or risk incurred directly or indirectly from the misinterpretation, misuse, or out-of-context application of our online content. Your health is your responsibility; seek individual professional care.
